Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...

There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from Bayer’s consumer health division. | There’s no need to dive fast and furious ...

With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket ...

While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a | ...

Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...

Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in ...

After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another ...

With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can ...

Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...

Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...

Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...

Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it ...